Lupus drug in breast milk: new study aims to find out

NCT ID NCT06594068

Recruiting now Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 22, 2026 · Updated 3 times

Summary

This study tracks 16 breastfeeding mothers with lupus who are taking anifrolumab. Researchers will measure how much of the drug appears in breast milk and in the mother's and baby's blood. The goal is to understand potential exposure and effects on the breastfed infant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anifrolumab
What this could lead to: If successful, this study could provide important safety data on anifrolumab use during breastfeeding, helping mothers with lupus make informed decisions.
What could go wrong: This is a small, observational registry (16 participants) focused on drug levels, not on treating lupus. It cannot prove the drug is safe for all infants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SYSTEMIC LUPUS ERYTHEMATOSUS

Contacts and locations

Locations

Research Site
RECRUITING

Las Vegas, Nevada, 89113, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.